Table 2.

Clinical data of AML patients and apoptosis induced in vitro by ssHHT

No.Age (y)Morphology (FAB)Leucocytes (×109/L)ResponseControlssHHT (15 ng/mL)
160AML5.1RE20.771.1
271AML204NT20.577.6
363M215.2RE46.180.9
455M135RE64.188.1
536M115CR19.787.1
635M481CR53.586.7
733M5a10RE15.753.6
855AML3.4RE38.594
974M22.4RE11.370.3
1035M174CR52.584
1122M217.6RE23.876.1
1242M193CR24.590.1
1335M521RE61.587.8
1467M478RE24.953
1576M127.4CR18.370.1
1670M60.7RE17.882.5
  • NOTE: Three AML patients were not classified for French-American-British classification. Responses are for conventional treatments (idarubicin or daunorubicin/Ara C).

  • Abbreviations: FAB, French-American-British classification for AML; CR, complete remission; RE, resistance to treatments; NT, nontreated.